The patient-reported outcomes for the new brand-generic teriflunomide in relapsing-remitting multiple sclerosis.
Roya AbolfazliSeyed Massood NabaviAmirreza AzimiMohammadali NahayatiKurosh GharagozliHamidreza TorabiMonireh GhazaeianZahra RezagholiSara SamadzadehPublished in: Clinical neurology and neurosurgery (2024)
Patients reported notable satisfaction with Teriflunomide, as reflected in their TSQM scores, which suggests a likelihood of improved patient adherence. The 14 mg brand-generic Teriflunomide was well-accepted by Iranian RRMS patients, with no significant concerns arising during the study. These findings also highlight the significance of patient-reported outcomes in DMTs, with potential benefits for adherence and clinical practice.